Beta Thalassemia Major Clinical Trial
Official title:
Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism
Verified date | August 2018 |
Source | First Affiliated Hospital of Guangxi Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Hematopoietic stem cell transplantation is currently the only way to cure thalassemia, one of
its main obstacles is the rejection after transplantation, chimerism continued to decline,
which eventually lead to transplant failure. chimerism is a key indicator of the succession
of immune response, which is a key indicator for predicting the failure of hematopoietic stem
cell transplantation and provides an important basis for early detection of rejection.
Transplantation of continuous chimerism can detect early unstable chimeras and rejection.The
chimerism rates after transplantation were continuously monitored using fluorescence labeled
multiplex PCR amplification of short tandem repeats (STR-PCR)
,and then follow our STR different rates for early interventional therapy to prevent further
reduction in chimerism leading to lead to graft failure.
Status | Active, not recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2019 |
Est. primary completion date | December 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Diagnosis of thalassemia major 2. There is no restriction on age or gender. 3. Underwent allogeneic hematopoietic stem cell transplantation, including sibling transplantation, unrelated transplantation and haploidentical transplantation. 4. On +45 day after transplantation, check patients with STR less than 80%. 5. Patients underwent reduce of dosage with a failure treatment by 6. Body condition score (ECOG score) is less than or equal to 1 point who meet follow-up conditions. Exclusion Criteria: Complicated with severe cardiac insufficiency and cardiac ejection fraction (EF) was lower than 50%. Complicated with severe pulmonary insufficiency (obstructive and / or restrictive ventilatory disorders). Complicated with severe liver function damage and liver function index (ALT or TBIL) is more than 2 times of the upper limit of the normal value. Complicated with severe renal dysfunction and renal function index (Cr or BUN) is 2 times of the upper limit of the normal value. Complicated with severe active bleeding |
Country | Name | City | State |
---|---|---|---|
China | the First Affiliated Hospital of Guangxi Medical University | Nanning | Guangxi |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital of Guangxi Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Chimerism after transplantation were monitored using fluorescence labeled multiplex PCR amplification of short tandem repeats (STR-PCR) | ß thalassemia major patients underwent reduced chimerism rate after allogeneic hematopoietic stem cell transplantation were collected and the chimerism rates after transplantation were continuously monitored using fluorescence labeled multiplex PCR amplification of short tandem repeats (STR-PCR).Monitoring once every 20-30 days after allogeneic hematopoietic stem cell transplantation.For patients with reduced chimerism, the results were grouped.We monitor STR-PCR once every 20-30 days after different treatment. | Change from chimerism rate at 2-3 months after different treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03276455 -
Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified
|
Phase 1/Phase 2 | |
Completed |
NCT02674607 -
the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children
|
N/A | |
Terminated |
NCT01571635 -
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
|
Phase 2 | |
Completed |
NCT04092205 -
Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation
|
Phase 2 | |
Completed |
NCT02744560 -
Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C
|
N/A | |
Recruiting |
NCT06466304 -
Inspiratory Muscle Training in Children With Beta Thalasemia
|
N/A | |
Recruiting |
NCT04353986 -
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders
|
Phase 3 | |
Not yet recruiting |
NCT02173951 -
An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
|
Phase 2/Phase 3 | |
Completed |
NCT03947632 -
Anthropometric Measurements in Children Having Transfusion-dependent Beta Thalassemia
|
||
Withdrawn |
NCT04776850 -
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
|
Early Phase 1 | |
Completed |
NCT02744547 -
Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C
|
N/A | |
Completed |
NCT02744105 -
Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C
|
N/A | |
Completed |
NCT02671695 -
Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia
|
N/A | |
Completed |
NCT00658385 -
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
|
N/A |